GENEGENETIC TECHNOLOGIES LTD

Nasdaq genetype.com


$ 0.89 $ 0.00 (0.01 %)    

Wednesday, 21-Aug-2024 15:59:59 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 0.90005
$ 0.78 x 100
-- x --
-- - --
$ 0.69 - $ 23.25
20,351
na
692,576
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genetic-technologies-transitions-to-a-capital-light-operating-model-with-lower-cost-operations-continued-focus-on-the-cos-core-business-of-easydna-and-genetype-working-capital-funded-by-short-term-800000-secured-loan-active-channel-partners-in-the-usa-with-genetype-sales-growth-easydna-sales-of-7m-and-growing

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based te...

 genetic-technologies-appoints-mark-ziirsen-as-chief-financial-officer

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tes...

 genetype-announces-the-introduction-of-suite-of-genetic-risk-assessment-tests-to-canada-and-new-zealand

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tes...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION